1. Home
  2. DSGN vs ATLO Comparison

DSGN vs ATLO Comparison

Compare DSGN & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • ATLO
  • Stock Information
  • Founded
  • DSGN 2017
  • ATLO 1903
  • Country
  • DSGN United States
  • ATLO United States
  • Employees
  • DSGN N/A
  • ATLO N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • DSGN Health Care
  • ATLO Finance
  • Exchange
  • DSGN Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • DSGN 208.9M
  • ATLO 180.3M
  • IPO Year
  • DSGN 2021
  • ATLO N/A
  • Fundamental
  • Price
  • DSGN $6.70
  • ATLO $20.86
  • Analyst Decision
  • DSGN
  • ATLO
  • Analyst Count
  • DSGN 0
  • ATLO 0
  • Target Price
  • DSGN N/A
  • ATLO N/A
  • AVG Volume (30 Days)
  • DSGN 195.7K
  • ATLO 23.7K
  • Earning Date
  • DSGN 11-07-2025
  • ATLO 10-17-2025
  • Dividend Yield
  • DSGN N/A
  • ATLO 3.83%
  • EPS Growth
  • DSGN N/A
  • ATLO 82.22
  • EPS
  • DSGN N/A
  • ATLO 1.79
  • Revenue
  • DSGN N/A
  • ATLO $60,568,000.00
  • Revenue This Year
  • DSGN N/A
  • ATLO N/A
  • Revenue Next Year
  • DSGN N/A
  • ATLO N/A
  • P/E Ratio
  • DSGN N/A
  • ATLO $11.64
  • Revenue Growth
  • DSGN N/A
  • ATLO 18.60
  • 52 Week Low
  • DSGN $2.60
  • ATLO $15.75
  • 52 Week High
  • DSGN $7.77
  • ATLO $21.48
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 55.49
  • ATLO 57.02
  • Support Level
  • DSGN $6.25
  • ATLO $20.68
  • Resistance Level
  • DSGN $6.77
  • ATLO $21.00
  • Average True Range (ATR)
  • DSGN 0.51
  • ATLO 0.44
  • MACD
  • DSGN 0.04
  • ATLO 0.06
  • Stochastic Oscillator
  • DSGN 73.58
  • ATLO 68.42

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.

Share on Social Networks: